These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 19499289)

  • 41. Soluble interleukin 2 receptors in patients with malignant lymphoma.
    Harrington DS; Patil K; Lai PK; Yasuda NN; Armitage JO; Ip SH; Weisenburger DD; Linder J; Purtilo DT
    Arch Pathol Lab Med; 1988 Jun; 112(6):597-601. PubMed ID: 2837161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Soluble interleukin-2 receptor levels in cerebrospinal fluid of patients with acute lymphocytic leukemia or with non-Hodgkin's lymphoma.
    Chang CS; Liu HW; Lin SF; Chen TP
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 May; 22(2):132-7. PubMed ID: 2605973
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease].
    Peng Q; Wu Q; Chen CH; Hong H; Zhang LY
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Jun; 8(3):208-10. PubMed ID: 16787593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Soluble interleukin-2 receptors in plasma cell dyscrasias.
    Takamatsu T; Yasuda N; Ohno T; Kanoh T; Uchino H; Fujii H
    Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):749-55. PubMed ID: 2618549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical factors indicating the presence of malignant lymphoma before lymph node dissection.
    Okumura Y; Nomura K; Kikuchi T; Suzuki T; Hidaka H; Ogawa T; Katori Y
    Acta Otolaryngol; 2015 May; 135(5):513-8. PubMed ID: 25719957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum levels of soluble interleukin-2 receptor in patients with ANCA-associated vasculitis.
    Arranz O; Ara J; Rodríguez R; Saurina A; Mirapeix E; Darnell A
    J Nephrol; 2000; 13(1):59-64. PubMed ID: 10720216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum concentrations of soluble interleukin-2 receptor in patients with malignant brain tumors.
    Yoshida S; Morii K
    J Surg Oncol; 2000 Oct; 75(2):131-5. PubMed ID: 11064393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum levels of interleukin-2 in cancer patients: preliminary considerations.
    Lissoni P; Viviani S; Santoro A; Barni S; Tancini G
    Int J Biol Markers; 1989; 4(4):203-6. PubMed ID: 2628500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Possible clinical significance of serum soluble interleukin-2 receptor level in primary bone lymphoma: two case reports.
    Yabe H; Ueno H; Ochi K; Morioka H; Yabe H; Terai C
    Case Rep Oncol; 2011 Mar; 4(1):125-31. PubMed ID: 21475602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The dynamic observation of serum level of SIL-2R and TNF in maxillary sinus cancer.
    Yu Y
    Chin Med Sci J; 2001 Sep; 16(3):168. PubMed ID: 12899331
    [No Abstract]   [Full Text] [Related]  

  • 53. Performance of serum soluble interleukin-2 receptor as a diagnostic marker for lymphoma in patients with fever.
    Kanda N; Yamaguchi R; Yamamoto Y; Matsumura M; Hatakeyama S
    Sci Rep; 2023 Nov; 13(1):18784. PubMed ID: 37914769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The radiologic clinical picture of primary bone lymphoma].
    Farrés MT; Dock W; Augustin I; Windhager R; Riegler M; Eibenberger K; Grabenwöger F
    Rofo; 1993 Jun; 158(6):589-93. PubMed ID: 8507852
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions.
    Murakami J; Arita K; Wada A; Mihara H; Origasa H; Kigawa M; Yasuda I; Sato T
    Mol Clin Oncol; 2019 Nov; 11(5):474-482. PubMed ID: 31620278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Study on the Pathogenesis of Pediatric Lymphoma Based on the Combination of Pseudotargeted and Targeted Metabolomics.
    Sun H; Chen N; Wang X; Li N; Wang S; Zhang Z; Zhou Y; Yang J
    Biomed Res Int; 2021; 2021():9984357. PubMed ID: 34124268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone scintiscan and malignant lymphoma.
    Ansari A; Lundquist VP; Azad M
    Ann Intern Med; 1976 Nov; 85(5):684-5. PubMed ID: 984634
    [No Abstract]   [Full Text] [Related]  

  • 58. [Malignant lymphoma of the elderly--evaluation of undiagnosed cases].
    Fukayama M; Murai Y; Ikebuchi K; Miwa A; Mori M
    Nihon Ronen Igakkai Zasshi; 1985 Nov; 22(6):564-7. PubMed ID: 3831462
    [No Abstract]   [Full Text] [Related]  

  • 59. A clinical study of bone lesions in malignant lymphoma.
    TAYLOR JH
    J Iowa State Med Soc; 1952 May; 42(5):214-8. PubMed ID: 14938666
    [No Abstract]   [Full Text] [Related]  

  • 60. Editor's comments: the role of inflammation in the development and progression of cancer.
    Gion M; Fabricio AS
    Int J Biol Markers; 2008; 23(2):67-8. PubMed ID: 18629777
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.